Inhibition of tumor promotion by parthenolide: Epigenetic modulation of p21

Cancer Prevention Research

Volumn 5, Issue 11, 2012, Pages 1298-1309

  Ghantous, Akram ^a   Saikali, Melody ^a   Rau, Tilman ^b   Gali Muhtasib, Hala ^a   Schneider Stock, Regine ^b   Darwiche, Nadine ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PARTHENOLIDE; PROTEIN P21; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; EPIGENETICS; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; SESQUITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870234556     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0230     Document Type: Article

References (50)

1. Yuspa SH. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis-thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res 1994;54:1178-89. (Pubitemid 24108054)
2. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998;23:144-58. (Pubitemid 28535818)
3. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011;12:1925-56.
4. Dhar A, Young MR, Colburn NH. The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 2002;234-235:185-93. (Pubitemid 34777856)
5. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: "one size does not fit all." Oncogene 2011;30:1615-30.
6. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759-66. (Pubitemid 32752455)
7. Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, et al. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 2001; 276:39713-20.
8. Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 2007;14:813-23. (Pubitemid 47081425)
9. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 2009;329:505-14.
10. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 2010;15:668-78.
11. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 1980;19:245-54. (Pubitemid 10154229)
12. Strickland JE, Greenhalgh DA, Koceva-Chyla A, Hennings H, Restrepo C, Balaschak M, et al. Development of murine epidermal cell lines which contain an activated rasHa oncogene and form papillomas in skin grafts on athymic nude mouse hosts. Cancer Res 1988;48:165-9. (Pubitemid 18030346)
13. Greenhalgh DA, Welty DJ, Player A, Yuspa SH. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc Natl Acad Sci U S A 1990;87:643-7.
14. Boukamp P. UV-induced skin cancer: similarities-variations. J Dtsch Dermatol Ges 2005;3:493-503.
15. Colburn NH, Wendel EJ, Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci U S A 1981;78:6912-6. (Pubitemid 12216872)
16. Ghantous A, Tayyoun AA, Lteif GA, Saliba NA, Gali-Muhtasib H, El-Sabban M, et al. Purified salograviolide A isolated from Centaurea ainetensis causes growth inhibition and apoptosis in neoplastic epidermal cells. Int J Oncol 2008;32:841-9. (Pubitemid 351780594)
17. The ImageJ image processing and analysis software. 2012. Available from: http://rsb.info.nih.gov/ij/index.html.
18. AliBaba2 software developed for transcriptional factors prediction to binding sites. 2011. Available from: http://www.gene-regulation.com/ pub/programs/alibaba2/index.html
19. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853-7.
20. Eto I. Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion. Cell Prolif 2000;33:167-87. (Pubitemid 30616163)
21. Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett 2007;254:119-27. (Pubitemid 47058812)
22. Shen HM, Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009; 14:348-63.
23. Straus DS. Design of small molecules targeting transcriptional activation by NF-κB: overview of recent advances. Expert Opin Drug Discov 2009;4:823-36.
24. Nomura M, Ma W, Chen N, Bode AM, Dong Z. Inhibition of 12-O-tetradecanoylphorbol- 13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 2000;21:1885-90.
25. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997;57:3569-76. (Pubitemid 27355509)
26. Basile JR, Eichten A, Zacny V, Munger K. NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res 2003;1:262-70. (Pubitemid 36292611)
27. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene 2003;22:1955-64. (Pubitemid 36523633)
28. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005;65: 9287-93. (Pubitemid 41507995)
29. Nishi K, Inoue H, Schnier JB, Rice RH. Cyclin D1 downregulation is important for permanent cell cycle exit and initiation of differentiation induced by anchorage-deprivation in human keratinocytes. J Cell Biochem 2009;106:63-72.
30. Weinberg WC, Fernandez-Salas E, Morgan DL, Shalizi A, Mirosh E, Stanulis E, et al. Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res 1999;59:2050-4. (Pubitemid 29217662)
31. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005;3:100-9. (Pubitemid 40271140)
32. Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A, et al. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med 2008;12:607-21. (Pubitemid 351555139)
33. Schneider-Stock R, Ghantous A, Bajbouj K, Saikali M, Darwiche N. Epigenetic mechanisms of plant-derived anticancer drugs. Front Biosci 2012;17:129-73.
34. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995;6:387-400.
35. Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, Tyner AL, et al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 2004;23:4173-6. (Pubitemid 38747949)
36. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-62. (Pubitemid 27175292)
37. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, et al. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005;24:2599-612. (Pubitemid 40593088)
38. Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, et al. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. Cancer Res 2001;61: 4160-8. (Pubitemid 32720985)
39. Ren Q, Kari C, Quadros MR, Burd R, McCue P, Dicker AP, et al. Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res 2006;66:5209-15. (Pubitemid 43844944)
40. Munshi A, Shafi G, Aliya N, Jyothy A. Histone modifications dictate specific biological readouts. J Genet Genomics 2009;36: 75-88.
41. Salisbury CM, Cravatt BF. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J Am Chem Soc 2008;130:2184-94. (Pubitemid 351287995)
42. Strickland J, Sun Y, Dong Z, Colburn NH. Grafting assay distinguishes promotion sensitive from promotion resistant JB6 cells. Carcinogenesis 1997;18:1135-8. (Pubitemid 28132502)
43. Tanaka K, Hasegawa J, Asamitsu K, Okamoto T. Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide. J Pharmacol Exp Ther 2005;315: 624-30. (Pubitemid 41500727)
44. Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet 2008;4:e1000258.
45. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 2010;30:1171-81.
46. Won YK, Ong CN, Shi X, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis 2004;25:1449-58. (Pubitemid 39162711)
47. Curry EA III, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22: 299-305. (Pubitemid 39012569)
48. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19: 4346-9.
49. McCarthy N. Epigenetics: worth another look? Nat Rev Cancer 2011;12:2-3.
50. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.